Vivo Capital »

Savara shares owned by Vivo Capital

Quarter-by-quarter ownership of Savara (SVRA) shares owned by Vivo Capital from 13F filings

Historical chart of Vivo Capital investment in Savara

Tip: Access up to 7 years of quarterly data

All positions including Savara held by Vivo Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Savara by Vivo Capital

Quarter filed Position value Share count Share price at filing
2024-03-31 $10M 2.1M 4.98
2023-12-31 $9.8M 2.1M 4.70
2023-09-30 $7.2M 1.9M 3.78

More positions owned by Vivo Capital

Soleno Therapeutics Common (SLNO)
Geron Corp Common (GERN)
Harmony Biosciences Holdings Common (HRMY)
Sinovac Biotech SHS (SVA)
Avadel Pharmaceuticals Adr (AVDL)
Verona Pharma Sponsored Ads (VRNA)
ALX Oncology Holdings Common (ALXO)
Dyne Therapeutics Common (DYN)
Terns Pharmaceuticals Common (TERN)
Astria Therapeutics Common (ATXS)
Viridian Therapeutics Common (VRDN)
Silence Therapeutics Ads (SLN)
Olema Pharmaceuticals Common (OLMA)
Adverum Biotechnologies Common
Alpine Immune Sciences Common (ALPN)

View all positions for Vivo Capital

Top funds holding Savara

NEA Management Company
Jennison Associates
Vanguard Group
Frazier Life Sciences Management
VR Adviser
Vivo Capital
Wellington Management Company
Henderson Group
Millennium Management
Nantahala Capital Management
Superstring Capital Management
Connor, Clark & Lunn Investment Management
Bank of New York Mellon
Charles Schwab Investment Management
Citadel Advisors

View all funds holding Savara